Director at Lucid Diagnostics (LUCD) receives 123,000-share restricted stock grant

Rhea-AI Filing Summary

Matheis Dennis reported acquisition or exercise transactions in this Form 4 filing.

Lucid Diagnostics Inc. director Dennis Matheis reported an equity award of 123,000 shares of common stock. These shares are structured as restricted stock granted under the company’s 2018 Equity Plan and were not purchased on the open market.

The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed. Following this grant, Matheis directly holds 788,443 shares of Lucid Diagnostics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Matheis Dennis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	123,000	$0.00	--

Holdings After Transaction: Common Stock — 788,443 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Matheis Dennis

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		123,000(1)	A	$0	788,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lucid Diagnostics (LUCD) director Dennis Matheis report?

Dennis Matheis reported receiving an award of 123,000 shares of Lucid Diagnostics common stock as restricted stock. The award was made under the company’s 2018 Equity Plan and reflects an equity-based compensation grant rather than an open-market stock purchase.

Are the 123,000 Lucid Diagnostics (LUCD) shares received by Dennis Matheis fully vested?

No, the 123,000 shares are restricted stock that vest on May 20, 2029. The award is subject to forfeiture if Matheis does not complete the requisite service period through that vesting date under the company’s 2018 Equity Plan.

Did Dennis Matheis buy Lucid Diagnostics (LUCD) shares in the market in this Form 4?

No, the Form 4 reports a grant of restricted stock at a stated price of $0.0000 per share. This indicates an equity compensation award, not an open-market purchase or sale of Lucid Diagnostics common stock by the director.

How many Lucid Diagnostics (LUCD) shares does Dennis Matheis own after this grant?

After the restricted stock grant, Dennis Matheis directly holds 788,443 shares of Lucid Diagnostics common stock. This total includes the newly granted 123,000 restricted shares, which remain subject to vesting and potential forfeiture conditions through May 20, 2029.

Under which plan was the Lucid Diagnostics (LUCD) restricted stock granted to Dennis Matheis?

The 123,000 restricted shares were granted under Lucid Diagnostics’ 2018 Equity Plan. This plan governs equity-based compensation awards, including restricted stock that typically vests over time and can be forfeited if specified service conditions are not satisfied.